Vertex Pharmaceuticals Incorporated: FDA Accepts Biologics L

First CRISPR gene-editing filings to be accepted for review by FDA - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT)

Related Keywords

Boston , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , San Francisco , California , Switzerland , Australia , Zeiten , Mecklenburg Vorpommern , Germany , London , City Of , America , American , Reshma Kewalramani , Susan Kim , Rachel Eides , Manisha Pai , Miroslava Minkova , Heather Nichols , Samarth Kulkarni , Stefan Klotter , Susie Lisa , European Hematology Association Congress On , Vertex Pharmaceuticals Incorporated Nasdaq , European Medicines Agency , Vertex Pharmaceuticals Incorporated , European Commission , Drug Administration , Instagram , Regulatory Agency , Twitter , Viacyte Inc , Exchange Commission , American Society Of Hematology Annual Congress , Youtube , Therapeutics Inc , European Hematology Association Congress , Linkedin , Vertex Pharmaceuticals , Companies To Work , Facebook , Priority Review , Standard Review , Pharmaceuticals Incorporated , Biologics License Applications , Prescription Drug User Fee Act , Annual European Hematology Association Congress , Chief Executive Officer , Regenerative Medicine Advanced Therapy , Fast Track , Orphan Drug , Rare Pediatric Disease , Marketing Authorization Applications , Orphan Drug Designation , Priority Medicines , Innovation Passport , Innovative Licensing , Access Pathway , New England Journal , American Society , Hematology Annual Congress , Gene Editing Process , Innovation District , North America , Top Employers , Private Securities Litigation Reform Act , While Vertex , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips ,